US 11,883,490 B2
Induction of IL-12 using immunotherapy
Michael Har-Noy, Jerusalem (IL)
Assigned to Mirror Biologics, Inc., Wesley Chapel, FL (US)
Filed by Mirror Biologics, Inc., Mesa, AZ (US)
Filed on May 20, 2021, as Appl. No. 17/326,009.
Application 17/326,009 is a division of application No. 14/962,728, filed on Dec. 8, 2015, granted, now 11,045,541.
Application 14/962,728 is a division of application No. 13/581,745, granted, now 9,233,156, issued on Jan. 12, 2016, previously published as PCT/US2012/036123, filed on May 2, 2012.
Claims priority of provisional application 61/582,881, filed on Jan. 4, 2012.
Claims priority of provisional application 61/564,551, filed on Nov. 29, 2011.
Claims priority of provisional application 61/528,484, filed on Aug. 29, 2011.
Claims priority of provisional application 61/482,009, filed on May 3, 2011.
Prior Publication US 2021/0268106 A1, Sep. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 38/20 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 39/085 (2006.01); A61K 38/17 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); A61K 39/385 (2006.01); A61K 39/44 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/19 (2013.01); A61K 38/20 (2013.01); A61K 38/21 (2013.01); A61K 39/085 (2013.01); A61K 39/385 (2013.01); A61K 39/44 (2013.01); C12N 5/0637 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/57 (2013.01)] 3 Claims
 
1. A method of treating a patient with a solid tumor, the method comprising:
inducing the production of endogenous IL-12 in the patient, wherein the endogenous IL-12 is induced by administering a composition comprising activated allogeneic Th1 cells to the patient, wherein the Th1 cells are activated by cross-linking CD3 and CD28;
ablating all or portion of the solid tumor in the patient to generate tissue necrosis along with intratumoral administration of the activated allogeneic Th1 cells;
measuring the level of endogenous IL-12 in the patient; and
readministering the composition until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml.